Search
Flumethasone
go.drugbank.com/drugs/DB00663ApprovedVet approvedFlumethasone is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of applicati...
Mixtures: LOCASALENE 0,2MG/G+30MG/G MERHEM, 30 GErtapenem
go.drugbank.com/drugs/DB00303ApprovedInvestigationalErtapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-posi...
Oliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by … [A218041] Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.[L15516]
Sinecatechins
go.drugbank.com/drugs/DB01266ApprovedInvestigationalNutraceuticalCatechins constitute 85 to 95% (by weight) of the total drug substance which includes more than 55% of Epigallocatechin gallate (EGCg), other catechin derivatives such as Epicatechin (EC), Epigallocatechin
Cilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigational[A243351, A243361, L39411] Cilgavimab is not approved for any indication by the FDA. … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Inosine
go.drugbank.com/drugs/DB04335ApprovedA purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose.
Relebactam
go.drugbank.com/drugs/DB12377ApprovedInvestigational[A181195,A181207] It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge.
Difenoxin
go.drugbank.com/drugs/DB01501ApprovedIllicitIt works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide … It is approved by the FDA to treat acute and chronic diarrhea.
Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigational[L49821] Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. … It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805]
Products: VITRAKVI ORAL SOLUTION 20MG/ML